Mingli Xiang

3.1k citations

69 papers · 2.6k indexed · h-index 29

Co-authors: Yuquan Wei Maling Gou Zhiyong Qian Lijuan Chen Shengyong Yang Liang Ma Shaochen ChenWei Zhu
Topics: Synthesis and biological activity (12 papers)Computational Drug Discovery Methods (10 papers)Nanoparticle-Based Drug Delivery (6 papers)
Cited by: Molecular Medicine Biomaterials Toxicology
Journals: Nature Communications PLoS ONE Biomaterials
Partner nations: China United States Canada

In The Last Decade

Mingli Xiang

68 papers receiving 2.6k citations

Peers

Countries citing papers authored by Mingli Xiang

Since Specialization

Citations

This map shows the geographic impact of Mingli Xiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mingli Xiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mingli Xiang more than expected).

Fields of papers citing papers by Mingli Xiang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mingli Xiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mingli Xiang. The network helps show where Mingli Xiang may publish in the future.

Co-authorship network of co-authors of Mingli Xiang

This figure shows the co-authorship network connecting the top 25 collaborators of Mingli Xiang. A scholar is included among the top collaborators of Mingli Xiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mingli Xiang. Mingli Xiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Summer Thermal Challenges in Emergency Tents: Insights into Thermal Characteristics of Tents with Air Conditioning 2024 ·Buildings ·Mingli Xiang,(unknown),(unknown),Wentao Zhang,Enshen Long	1
2	Discovery of 3-(4-(2-((1H-Indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile Derivatives as Selective TYK2 Inhibitors for the Treatment of Inflammatory Bowel Disease 2021 ·Journal of Medicinal Chemistry ·Chufeng Zhang,(unknown),Yong Li,Minghai Tang,Tao Yang,(unknown),Yong Chen,(unknown),Mingli Xiang,Lijuan Chen	16
3	N-(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms 2020 ·Journal of Medicinal Chemistry ·Tao Yang,(unknown),Yong Chen,Mingli Xiang,Minghai Tang,(unknown),Mingsong Shi,Jun He,Xue Yuan,Chufeng Zhang,(unknown),(unknown),Zhuang Yang,Lijuan Chen	13
4	Identification of Pyrrolo[2,3-d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia 2019 ·Journal of Medicinal Chemistry ·Xue Yuan,Yong Chen,(unknown),Jun He,Lei Lei,Minghai Tang,Jiang Liu,(unknown),(unknown),Tao Yang,(unknown),Shengyong Yang,Yuquan Wei,Aihua Peng,Ting Niu,Mingli Xiang,Haoyu Ye,Lijuan Chen	31
5	Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms 2019 ·Journal of Medicinal Chemistry ·Tao Yang,(unknown),(unknown),Zhuang Yang,Minghai Tang,Jun He,Yong Chen,Peng Bai,Xue Yuan,Chufeng Zhang,(unknown),(unknown),Mingli Xiang,Lijuan Chen	31
6	Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis 2019 ·European Journal of Medicinal Chemistry ·Chufeng Zhang,Heying Pei,Jun He,Jiali Zhu,Weimin Li,Ting Niu,Mingli Xiang,Lijuan Chen	25
7	Applying an innovative biodegradable self-assembly nanomicelles to deliver α-mangostin for improving anti-melanoma activity 2019 ·Cell Death and Disease ·Shuping Yang,Xiang Gao,Yihong He,Yuzhu Hu,Bocheng Xu,Zhiqiang Cheng,Mingli Xiang,Yongmei Xie	16
8	Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis 2018 ·Scientific Reports ·Heying Pei,Linhong He,Mingfeng Shao,Zhuang Yang,Yan Ran,Dan Li,Yuanyuan Zhou,Minghai Tang,Taijin Wang,Yanqiu Gong,Xiaoxin Chen,Shengyong Yang,Mingli Xiang,Lijuan Chen	33
9	Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis 2017 ·European Journal of Medicinal Chemistry ·Linhong He,Heying Pei,Chufeng Zhang,Mingfeng Shao,Dan Li,(unknown),(unknown),Xiaoxin Chen,Mingli Xiang,Lijuan Chen	17
10	Improving the anti-ovarian cancer activity of docetaxel with biodegradable self-assembly micelles through various evaluations 2015 ·Biomaterials ·Xiang Gao,Shimin Wang,Bilan Wang,Senyi Deng,Xiaoxiao Liu,Xiaoning Zhang,(unknown),Rangrang Fan,Mingli Xiang,Chao You,Yuquan Wei,Zhiyong Qian,Gang Guo	51
11	Scaffold-based design of xanthine as highly potent inhibitors of DPP-IV for improving glucose homeostasis in DIO mice 2015 ·Molecular Diversity ·Yan Ran,Heying Pei,Caifeng Xie,Liang Ma,Yuzhe Wu,Kai Lei,Mingfeng Shao,Minghai Tang,Mingli Xiang,Aihua Peng,Yuquan Wei,Lijuan Chen	5
12	Combining structure-based pharmacophore modeling, virtual screening, and in silico ADMET analysis to discover novel tetrahydro-quinoline based pyruvate kinase isozyme M2 activators with antitumor activity 2014 ·Drug Design Development and Therapy ·Gu He,Can Chen,(unknown),(unknown),Liang Ouyang,Mingli Xiang,Qinglin Jiang,Wei Huang,Cheng Peng	25
13	Design, synthesis and biological evaluation of a series of pyrano chalcone derivatives containing indole moiety as novel anti-tubulin agents 2014 ·Bioorganic & Medicinal Chemistry ·Guangcheng Wang,Chunyan Li,Lin He,Kai Lei,Fang Wang,(unknown),Zhuang Yang,Dong Cao,Liang Ma,Jinying Chen,(unknown),Xiaolin Liang,Mingli Xiang,Aihua Peng,Yuquan Wei,Lijuan Chen	100
14	In silico identification of EGFR-T790M inhibitors with novel scaffolds: start with extraction of common features 2013 ·Drug Design Development and Therapy ·Mingli Xiang,Kai Lei,(unknown),Yu‐Chun Lin,Gu He,Mingli Yang,Lijuan Chen,Yirong Mo	13
15	Synthesis of novel spirooxindolo-pyrrolidines, pyrrolizidines, and pyrrolothiazoles via a regioselective three-component [3+2] cycloaddition and their preliminary antimicrobial evaluation 2013 ·Molecular Diversity ·(unknown),Liang Ouyang,Jie Liu,(unknown),Wei Huang,Bo Han,Fengbo Wu,Gu He,Mingli Xiang	55
16	Computer-Aided Drug Design: Lead Discovery and Optimization 2012 ·Combinatorial Chemistry & High Throughput Screening ·Mingli Xiang,Yu Cao,(unknown),Lijuan Chen,Yirong Mo	65
17	Curcumin-loaded biodegradable polymeric micelles for colon cancer therapy in vitro and in vivo 2011 ·Nanoscale ·Maling Gou,Ke Men,Shi H,Mingli Xiang,Juan Zhang,Jia Song,Jianlin Long,Yang Wan,Feng Luo,Xia Zhao,Zhiyong Qian	348
18	Detailed conformational dynamics of juxtamembrane region and activation loop in c‐Kit kinase activation process 2008 ·Proteins Structure Function and Bioinformatics ·Jun Zou,(unknown),(unknown),Mingli Xiang,Bing Shi,Yuquan Wei,Shengyong Yang	23
19	Support vector machine and pharmacophore-based prediction models of multidrug-resistance protein 2 (MRP2) inhibitors 2008 ·European Journal of Pharmaceutical Sciences ·Hui Zhang,Mingli Xiang,Yinglan Zhao,Yuquan Wei,Shengyong Yang	15
20	Pharmacophore Modelling and Virtual Screening for Identification of New Aurora‐A Kinase Inhibitors 2008 ·Chemical Biology & Drug Design ·(unknown),Huiyuan Wang,Yinglan Zhao,Mingli Xiang,Peidu Jiang,Zhixing Cao,Yuzhu Zheng,(unknown),Luoting Yu,Yuquan Wei,(unknown)	43

About Mingli Xiang

Mingli Xiang is a scholar working on Toxicology, Organic Chemistry and Computational Theory and Mathematics, having authored 69 papers that have together received 2.6k indexed citations. Recurring topics across this work include Synthesis and biological activity (12 papers), Computational Drug Discovery Methods (10 papers) and Nanoparticle-Based Drug Delivery (6 papers). The work is most often cited by research in Molecular Medicine (334 citations), Biomaterials (512 citations) and Toxicology (111 citations). Mingli Xiang has collaborated with scholars based in China, United States and Canada. Frequent co-authors include Yuquan Wei, Maling Gou, Zhiyong Qian, Lijuan Chen, Shengyong Yang, Liang Ma, Shaochen Chen, Wei Zhu, Ke Men and Jia Song. Their work appears in journals such as Nature Communications, PLoS ONE and Biomaterials.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact